Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Backgrounds ALT ≥ 80 U/L and HBV DNA ≥ 2000 IU/ml are treatment criteria of APASL guidelines for chronic hepatitis B (CHB) patients. The need of antiviral therapy for patients in gray zone (ALT

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology international 2021-12, Vol.15 (6), p.1421-1430
Hauptverfasser:	Teng, Wei, Chang, Ting-Tsung, Yang, Hwai-I, Peng, Cheng-Yuan, Su, Chien-Wei, Su, Tung-Hung, Hu, Tsung-Hui, Yu, Ming-Lung, Yang, Hung-Chih, Wu, Jaw-Ching
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antiviral agents Antiviral Agents - therapeutic use Antiviral drugs Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - epidemiology Colorectal Surgery Deoxyribonucleic acid Derivation DNA DNA, Viral Genetics Guidelines Hepatitis B Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Hepatocellular carcinoma Hepatology Humans Interferon Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - epidemiology Male Medicine Medicine & Public Health Original Article Patients Risk Risk Factors Risk groups Surgery Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Backgrounds ALT ≥ 80 U/L and HBV DNA ≥ 2000 IU/ml are treatment criteria of APASL guidelines for chronic hepatitis B (CHB) patients. The need of antiviral therapy for patients in gray zone (ALT
ISSN:	1936-0533 1936-0541
DOI:	10.1007/s12072-021-10263-x